AKT1 and Miyoshi myopathy: Remarkably, the treatment of MM cells with GSK-3 inhibitors together with BZ resulted in an even further increase of PARP cleavage and reduction of phospho-Ser 473 AKT levels, total AKT and MCL-1 protein levels (Fig. 4B).